Financial Post
🏢 Postmedia
May 18, 2026
· 1 min read
AI Analyzed
✓ Established
View full audit trail →
JASCAYD® (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
-1.00 · LEFT
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
0.000 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.026
5,039 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables access to the first oral PDE4B inhibitor with antifibrotic and immunomodulatory effects authorized for use in IPF and PPF, and the first new treatment in […]
Read full article at Financial Post ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
May 18, 2026
📰
🔒 Unlock — Starter+
1 outlet covered this story
Side-by-side comparison · bias by outlet · framing analysis